Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $725

Benzinga · 4d ago
Goldman Sachs analyst Salveen Richter maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $654 to $725.